Most strikingly, the SELECT trial demonstrated that semaglutide significantly reduced MACE in individuals without T2DM but with overweight or obesity and established CV risk (HR 0.80), making it the first GLP-1 RA approved for CV risk reduction in a non-diabetic population (32). Here, GCG is linked to Obesity.